Trial Profile
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Doxorubicin
- Indications Carcinoma; Liver cancer
- Focus Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
- Acronyms SPACE
- Sponsors Bayer; Bayer HealthCare
- 12 Jul 2019 This trial has been completed in France, according to European Clinical Trials Database.
- 22 Jan 2016 Results published in the Journal of Hepatology
- 21 Sep 2012 Planned end date changed from 1 Jul 2012 to 1 Apr 2013 as reported by ClinicalTrials.gov.